CG Oncology, a biotech firm, sees a 96% surge in its debut following an enlarged IPO | |
This past week saw the pricing of seven Initial Public Offerings (IPOs), with three of them raising more than $100 million each, marking a significant week for the stock market. CG Oncology (CGON) stood out among the companies that went public. After revising the terms of its offering earlier in the week, CGON further upsized its offering and priced it above the initial range. This move allowed the company to raise a substantial $380 million, resulting in a market capitalization of $1.3 billion. CGON’s sole clinical asset, a treatment initially developed for a specific type of bladder cancer, is currently undergoing a Phase 3 trial. The company expects to have topline data from this trial by the end of 2024. If the trial proves successful, CGON believes it could form the basis for a Biologics License Application (BLA) submission. Investors responded positively to CGON’s IPO, with the company’s stock price surging 96% on its first day of trading and ending the week up 84%. For more details please visit our website - https://www.medhealthinsight.com/new-soundboard-review-pricing-is-not-always-the-only-criteria-2-4/ ![]() | |
Related Link: Click here to visit item owner's website (0 hit) | |
Target State: All States Target City : New York City Last Update : 08 August 2025 4:41 PM Number of Views: 44 | Item Owner : medhealthinsight Contact Email: (None) Contact Phone: (None) |
Friendly reminder: Avoid scams and fraud on internet. Click here to read some tips. |